Cefuroxime axetil has been evaluated previously in the treatment of lower respiratory tract infections, but not specifically in the treatment of community-acquired pneumonia. In a multicentre, investigator-blinded clinical trial, 162 patients with community-acquired pneumonia were randomly assigned to receive orally either cefuroxime axetil 500 mg bid (n = 84) or amoxycillin/clavulanate 500 mg/125 mg tid (n = 78) for 10 days. Organisms were isolated from the pretreatment sputum specimens of 97 of 162 (60%) patients, the commonest isolates being Streptococcus pneumoniae (38%) and Haemophilus influenzae (18%). A satisfactory clinical outcome (cure or improvement) was achieved in 100% (55 of 55) and 96% (49 of 51) of the clinically evaluable patients treated with cefuroxime axetil or amoxycillin/clavulanate, respectively (P = 0.23). With respect to eradication of bacterial pathogens, a satisfactory outcome (cure, presumed cure or cure with colonization) was obtained in 94% (32 of 34) and 93% (37 of 40) of bacteriologically evaluable patients treated with cefuroxime axetil or amoxycillin/clavulanate, respectively (P=1.00). Both treatment regimens used in this study were well tolerated. The most common drug-related adverse experiences were gastrointestinal events, reported by 8% and 4%, respectively, of the patients in the amoxycillin/clavulanate and cefuroxime axetil groups, a difference which was not statistically significant (P = 0.32). These results indicate that cefuroxime axetil twice a day is as effective as amoxycillin/clavulanate three times a day in the treatment of outpatients with mild to moderate community-acquired pneumonia.
Introduction
Pneumonia is a common condition, occurring at an overall rate of 12 cases per 1000 persons per year in the USA (Marrie, 1994) . Pneumonia is the sixth leading cause of death in the USA, and it is estimated that the cost of treating pneumonia is $14 billion in direct patient care costs and $9 billion in lost wages (Marrie, 1994) . The most common pathogen implicated in community-acquired pneumonia continues to be Streptococcus pneumoniae, followed by Haemophilus influenzae, although the number 556 F. Higuera et at.
of cases of pneumonia due to 'atypical' pathogens such as Legionella spp., Mycoplasma pneumoniae, and Chlamydia pneumoniae has risen in recent years (Marrie, 1994) .
Cefuroxime axetil is an oral ester prodrug of the second-generation cephalosporin cefuroxime. Cefuroxime is characterized by a high degree of stability to /J-lactamases (Emmerson, 1988) and demonstrates favourable in-vitro activity against a wide range of Gram-positive and Gram-negative organisms, including the common pathogens associated with pneumonia (Jorgensen et al., 1990; Murray, 1991; Murray et al., 1993; Washington et al., 1993) . Amoxycillin in combination with the /Mactamase inhibitor clavulanate potassium is similarly active in vitro against botĥ -lactamase producing and non-/?-lactamase producing strains of H. influenzae and Moraxella catarrhalis (Todd & Benfield, 1990) . The clavulanate component is largely responsible for in-vitro activity against the clinically important plasmid mediated /Mactamases frequently responsible for transferred drug resistance to penicillins and cephalosporins.
Cefuroxime axetil has been compared with amoxycillin/clavulanate in four earlier clinical trials in patients with lower respiratory tract infections (Mayhew, 1987; Hugonot et al., 1990; Contardi, 1992; Schnelle, 1992) . However, these studies focused primarily on cases of acute bronchitis and none of the studies examined the efficacy of the two antibiotics in a population consisting solely of patients with communityacquired pneumonia. The purpose of the present study was to compare the clinical efficacy and safety of 10 days' treatment with cefuroxime axetil 500 mg bid with amoxycillin/clavulanate potassium 500mg/125mg tid in patients with communityacquired pneumonia.
Methods

Patient selection
This investigator-blinded, prospective, randomized study was conducted at 31 centres throughout the USA and Latin America. Outpatients admitted to the study were 12 years of age or older with community-acquired pneumonia. Diagnosis was confirmed by a chest X-ray (read by a radiologist) showing localized infiltrates with or without pleural effusion, the presence of two of five clinical symptoms (fever ^ 100.5°F (oral), chills, recent onset of productive cough, shortness of breath, or pleuritic chest pain), and the presence of at least two of five physical signs (tachypnoea, egophony, rales, dullness to percussion, and bronchial breath sounds). Patients also had to have either leucocytosis (> 10 x 10'/L white blood cells) or > 15% band cells, and/or a positive culture of a susceptible pathogen from bronchopulmonary secretions. Patients were excluded if they were pregnant or lactating, had a history of a hypersensitivity reaction to any of the study drugs, had received other antibiotics within 72 h before enrolment, or had neutropenia or significant underlying disease, including pulmonary disease marked by abnormal baseline pulmonary function tests (pO 2 < 60 mmHg or pCO 2 > 55 mmHg), or an underlying condition known to compromise their ability to eradicate bacterial infections. The study protocol was approved by an Institutional Review Board at each centre, and all patients provided written informed consent.
Microbiological investigations
A blood culture and an appropriate respiratory tract fluid specimen for culture (deep expectorated sputum, endotracheal suction, bronchial washing, or transtracheal aspirate) were obtained before starting treatment. Gram staining of sputum specimens was performed and only cultures from specimens containing < 10 epithelial cells/lpf and >25 polymorphonuclear leucocytes/lpf were considered acceptable. To be considered bacteriologically evaluable, a culture had to be obtained within 48 h before the start of therapy. The infecting organism(s) was identified and tested for susceptibility to both cefuroxime and amoxycillin/clavulanate by the Kirby-Bauer method using the corresponding 30 jig discs or by a tube or agar dilution MIC determination, using breakpoints established by the National Committee for Clinical Laboratory Standards (National Committee for Clinical Laboratory Standards, 1983 Standards, , 1988 .
Antimicrobial therapy
Patients were assigned according to a computer-generated randomization code to receive 10 days' treatment with either cefuroxime axetil 500 mg bid or amoxycillin/ clavulanate 500 mg/125 mg tid. Patients were instructed to take cefuroxime axetil after eating, since absorption is enhanced by food (Finn et al., 1987) , whereas amoxycillin/clavulanate was administered without regard to meals. To ensure investigator blinding, study drugs were dispensed to patients by the pharmacy or study coordinator, and patients were instructed not to discuss the frequency of dosing with the investigator. A urine specimen (;> 10 mL) was obtained 3 to 5 days after the start of treatment and assessed by a biological assay for the presence of antibiotic in order to confirm compliance with therapy. In addition, patients returned the medication container at mid-course and first post-treatment visits so that compliance could also be assessed by tablet count. The tablet count was conducted by the study coordinator in order to maintain the investigator-blinded nature of the study.
Clinical and bacteriological evaluations
Patients were evaluated for clinical symptoms and physical signs of infection 3 to 5 days after starting treatment, 1 to 3 days post-treatment, and 14 days post-treatment. A follow-up chest X-ray was taken at 14 days post-treatment to determine any therapy related changes. The clinical response of each patient was categorised as follows: (1) cure (complete resolution of clinical signs and symptoms of infection at the 1 to 3 day and 14 day post-treatment visits); (2) improvement (clinical signs and symptoms substantially reduced, but not completely resolved); (3) failure (no apparent response to treatment after 3 or more days of therapy); (4) recurrence (cure at 1-3 days post-treatment, but with recurrence of clinical symptoms during the follow-up period or at 14 days post-treatment). Patients were considered clinically unevaluable if they received less than 3 days of treatment with the study drug, did not conform to selection criteria, had a pathogen in the pre-treatment culture that was resistant to either of the study drugs, received concomitant treatment with a non-study antimicrobial agent, or if they had another significant protocol deviation.
Bacterial response to treatment was defined as follows: (1) cure (eradication of the initial pathogen from subsequent cultures); (2) presumed care (culturable material not F. Hlguera et al.
available at the mid-course or post-treatment visits due to clinical improvement); (3) failure (initial pathogen still present after 3 or more days of therapy without eventual clearance); (4) presumed failure (culturable material not available at the time the patient was discontinued from the study with an unsatisfactory clinical response); (5) recurrence (eradication and then re-isolation of the initial pathogen); (6) cure with colonization (eradication of initial pathogen plus isolation of at least one new organism not associated with clinical symptoms); (7) cure with superinfection (eradication of initial pathogen plus isolation of at least one new pathogen associated with clinical symptoms requiring continued, additional, or alternative therapy); and (8) failure with superinfection (no eradication of initial pathogen plus isolation of at least one new pathogen requiring additional or alternative therapy).
Patients were bacteriologically unevaluable if the pre-treatment culture was negative or yielded a pathogen resistant to either study drug, the pre-treatment isolate was not tested for sensitivity, follow-up cultures were not performed when culturable material was available, they received less than 3 days of treatment with the study drug, they received concomitant treatment with a non-study antimicrobial agent to which the pathogen would be expected to be sensitive, or they had another significant protocol deviation. Patients with negative pre-treatment cultures remained in the study for the evaluation of clinical efficacy. However, patients with pre-treatment pathogens resistant to either of the study drugs were considered both clinically and bacteriologically unevaluable and were withdrawn from the study.
Safety evaluations
At each visit, adverse events were assessed by investigators for severity, duration, and the relationship to treatment. Laboratory tests were performed only if clinically indicated.
Statistical analyses
A two-tailed Fisher's Exact test was used to ascertain differences between treatment groups in clinical and bacteriological efficacy and in incidence of adverse events. The Wilcoxon rank sum test was used to compare age, height, and weight, and the Mantel-Haenszel test was used to compare sex and ethnic origin. A P value of ^0.05 was considered to be statistically significant.
Results
A total of 162 patients with community-acquired pneumonia were enrolled in the study between November, 1988 and June, 1991, of which 84 were treated with cefuroxime axetil and 78 were treated with amoxycillin/clavulanate. Of the 162 patients in the study, 94 (58%) were enrolled at the three Latin American centres and 68 patients (42%) were enrolled at centres in the USA. A majority of the USA centres did not begin enrolling patients until December, 1990, when the study had already been under way for 2 years; these centres were open for enrolment for only approximately half a year. There were no statistically significant differences between groups with respect to demographic characteristics (Table I ). The pre-treatment chest X-ray revealed that 79 (94%) and 77 (99%) of the patients in the cefuroxime axetil group and the amoxycillin/clavulanate group, respectively, had lobar infiltrate or consolidation; the remaining patients presented with either lobar cavitation or pleural effusion.
The duration of dosing ranged from 3 to 12 days for the cefuroxime axetil group and from 3 to 13 days for the amoxycillin/clavulanate group. The mean and median dosing duration with both study drugs was 10 days. No patient received more than the targeted amount of 20 cefuroxime axetil doses and 30 amoxycillin/clavulanate doses. Excellent compliance was seen with both of the assigned treatment regimens; antibiotic activity was detected in the urine of all patients receiving either cefuroxime axetil or amoxycillin/clavulanate.
Clinical outcome
Table II presents the clinical outcome of patients in the two treatment groups. Of the 162 patients enrolled, 106 (65%) were clinically evaluable. The primary reason that patients were clinically unevaluable was because they were enrolled but did not comply with selection criteria (34 of 56 unevaluable patients (61%)); no study patient was unevaluable because of non-compliance with the treatment regimen. A satisfactory clinical response (cure or improvement) was obtained in 100% and 96% of clinically evaluable patients treated with cefuroxime axetil or amoxycillin/ clavulanate, respectively (P = 0.23). Both treatment failures in the amoxycillin/ clavulanate group occurred in patients from whom no pretreatment pathogen was isolated. 
Bacteriological outcome
Seventy-four (46%) of the 162 patients enrolled were bacteriologically evaluable (Table III) , primarily reflecting the difficulty of isolating pathogens from sputum specimens (54 of 88 unevaluable patients (61%)). Eleven of these patients (six in the cefuroxime axetil group (12%) and five in the amoxycillin/clavulanate group (13%)) were unevaluable because the pretreatment isolate was resistant to one of the study drugs. A satisfactory bacteriological response (cure, presumed cure, or cure with colonization) was obtained in 94% and 93% of bacteriologically evaluable patients treated with cefuroxime axetil and amoxycillin/clavulanate, respectively (P = 1.00). The unsatisfactory bacteriological outcomes occurred in patients yielding S. pneumoniae or H. influenzae as the pretreatment pathogens (cefuroxime axetil group, one of each; amoxycillin/clavulanate group, two S. pneumoniae and one H. influenzae). 'Adverse events are not necessarily additive since some patients reported more than one adverse event.
Treatment comparisons of incidence were performed using Fisher's exact test.
Bacterial isolates were obtained from the pre-treatment sputum specimens of 97 of 162 (60%) study patients. Of the 111 pathogens isolated, 93% were sensitive to both cefuroxime and amoxycillin/clavulanate. The primary pathogens isolated were S. pnenmoniae (38%) and H. influenzae (18%), with 15% of the H. influenzae isolates producing /Mactamase.
Safety analyses
There were no statistically significant differences between cefuroxime axetil and amoxycillin/clavulanate treatment groups in the incidence of drug-related adverse events (Table IV) . The most common adverse events were gastrointestinal, reported by 8% of patients in the amoxycillin/clavulanate group and 4% of patients in the cefuroxime axetil group (P = 0.315).
Discussion
The results of the present study indicate that 10 day dosing with cefuroxime axetil 500 mg bid is as effective, both clinically and bacteriologically, as 10 day dosing with amoxycillin/clavulanate 500 mg/125 mg tid in the treatment of outpatients with mild to moderate community-acquired pneumonia. In addition, both treatment regimens were well tolerated. The results also demonstrate that both antibiotics were effective against the pathogens most commonly associated with community-acquired pneumonia, S. pneumoniae and H. influenzae.
In a previous comparative clinical trial involving 486 patients with lower respiratory tract infections, including pneumonia (Mayhew, 1987) , 7 days' treatment with cefuroxime axetil 500 mg bid and a lower dose of amoxycillin/clavulanate (250 mg/125 mg) tid achieved comparable clinical cure/improvement rates (94% vs 93%) and bacteriological eradication rates (90% for both antibiotics), results which are very similar to those obtained in our study. Only one other clinical trial in patients with lower respiratory tract infections compared cefuroxime axetil and amoxycillin/clavu-F. Higuera et al. lanate at the dosages used in the present study (Schnelle, 1992) . However, these patients had acute exacerbations of chronic bronchitis, not pneumonia. In this 10 day treatment study, cefuroxime axetil and amoxycillin/clavulanate again produced similar clinical cure rates (96% vs 97%) and bacteriological eradication rates (90% vs 92%).
The high degree of efficacy of cefuroxime axetil in community-acquired pneumonia may be partly related to the concentrations of cefuroxime achieved in the lower respiratory tract. Although there have been no human studies to date to assess cefuroxime concentrations in lung tissue following administration of cefuroxime axetil, studies measuring cefuroxime in sputum and bronchial tissue have been reported (Walstad et al., 1988; Wise et al., 1989; Winter & Dhillon, 1991) . Walstad et al. (1988) reported a mean sputum cefuroxime concentration of 2.8 mg/L at 3 h following a 500 mg post-meal dose of cefuroxime axetil. Following a 500 mg dose taken under fasting conditions, mean cefuroxime concentrations in bronchial mucosa were 3.6 ± 1.0 ng/g between 0.5 and 6.2 h post-dose in one study (Wise et al., 1989) and 2.2 ± 0.8 ^g/g between 2.1 and 3.4 h postdose in another study (Winter & Dhillon, 1991) . These concentrations exceed the MIC90 values for cefuroxime of most strains of S. pneumoniae and H. influenzae. Since absorption of cefuroxime is greater when cefuroxime axetil is taken with meals, concentrations in bronchial tissue would be expected to be higher than demonstrated above under fasting conditions. No significant differences in the incidence of gastrointestinal adverse events were found in this study between the two drug regimens examined. No statistically significant differences in the incidence of adverse events was observed in four earlier clinical trials that compared tablet formulations of cefuroxime axetil 250 to 500 mg bid with a lower dose of amoxycillin/clavulanate (250mg/125 mg) tid over 5-10 days (Mayhew, 1987; Watts, Williams & Cox, 1987; Hebblethwaite, Brown & Cox, 1987; Tremblay, Dubois & Guertin, 1992) , and in one previous trial that compared cefuroxime axetil 500 mg bid with amoxycillin/clavulanate (500 mg/125 mg) tid over a 10 day period (Schnelle, 1992) . All of these studies involved patients with infections other than pneumonia. However, in three other comparative clinical trials with amoxycillin/clavulanate (Roge, Durand & Pappo, 1989; Hugonot et al., 1990; Camacho et al., 1992) , including the largest one performed to date, involving 317 patients with acute sinusitis (Camacho et al., 1992) , therapeutic regimens of cefuroxime axetil tablets were associated with significantly fewer drug-related adverse events, particularly diarrhoea and other gastrointestinal symptoms. Similarly, where 10 days' treatment with the suspension formulations of the two drugs were compared in more than 600 paedriatric patients with acute otitis media (Pichichero et al., 1990; McLinn et al., 1994) , cefuroxime axetil resulted in significantly fewer drug-related adverse events and significantly less diarrhoea. No comparative clinical trial to date has reported amoxycillin/clavulanate to be better tolerated than cefuroxime axetil.
The choice of an oral antibiotic for the treatment of community-acquired pneumonia requires not only consideration of clinical and bacteriological efficacy and adverse event profile, but also consideration of dosage convenience. In this regard, the twice daily dosing with cefuroxime axetil is advantageous compared with the three times daily dosing regimen of amoxycillin/clavulanate. In addition, the broad-spectrum antibacterial activity of cefuroxime axetil, including excellent activity against the major pathogens of the lower respiratory tract (Jorgensen et al., 1990; Murray, 1991; Murray el al., 1993; Washington et al., 1993) , as well as its high degree of stability to /J-lactamases (Emmerson, 1988) , supports its use in the treatment of patients with mild to moderate community-acquired pneumonia.
